share_log

Elevai Labs | 10-Q: Q3 2024 Earnings Report

Elevai Labs | 10-Q: Q3 2024 Earnings Report

Elevai Labs | 10-Q:2024財年三季報
美股SEC公告 ·  2024/11/15 00:25

Moomoo AI 已提取核心訊息

Elevai Labs reported Q3 2024 revenue of $527,478, slightly down from $554,654 in Q3 2023, while achieving an improved gross margin of 75% compared to 66% year-over-year. The company's flagship Enfinity product sales increased 10% to 2,616 units, though Empower product sales declined 40%. Operating expenses rose to $1.31 million from $1.15 million in the prior year period.The company strengthened its financial position by completing a $7 million public offering in September 2024, issuing 28.57 million shares and warrants. Additionally, Elevai expanded its product portfolio by acquiring two key licenses - a stem cell formulation technology license for $1 million and an exclusive license for engineered probiotic products from MOA Life Plus.Management implemented strategic changes including executive restructuring, with Graydon Bensler appointed as CEO and Braeden Lichti as Chairman. The company also streamlined operations by reducing headcount and secured a $200,000 revolving credit facility. As of September 30, 2024, Elevai maintained a cash position of $6.43 million with working capital of $6.1 million.
Elevai Labs reported Q3 2024 revenue of $527,478, slightly down from $554,654 in Q3 2023, while achieving an improved gross margin of 75% compared to 66% year-over-year. The company's flagship Enfinity product sales increased 10% to 2,616 units, though Empower product sales declined 40%. Operating expenses rose to $1.31 million from $1.15 million in the prior year period.The company strengthened its financial position by completing a $7 million public offering in September 2024, issuing 28.57 million shares and warrants. Additionally, Elevai expanded its product portfolio by acquiring two key licenses - a stem cell formulation technology license for $1 million and an exclusive license for engineered probiotic products from MOA Life Plus.Management implemented strategic changes including executive restructuring, with Graydon Bensler appointed as CEO and Braeden Lichti as Chairman. The company also streamlined operations by reducing headcount and secured a $200,000 revolving credit facility. As of September 30, 2024, Elevai maintained a cash position of $6.43 million with working capital of $6.1 million.
Elevai Labs報告2024年第三季度營業收入爲527,478美元,較2023年第三季度的554,654美元略有下降,同時實現了75%的毛利率,相比去年66%有所改善。公司的旗艦產品Enfinity銷量增加10%,達到2,616台,儘管Empower產品銷量下降了40%。營業費用從去年同期的115萬增加到131萬。公司通過在2024年9月完成700萬的公開發行來增強其財務狀況,發行了2857萬股股票和Warrants。此外,Elevai通過收購兩項關鍵許可擴展了其產品組合 - 一項價值100萬的幹細胞製劑科技許可和從Moa Life Plus獲得的專有工程益生菌產品許可。管理層實施了戰略...展開全部
Elevai Labs報告2024年第三季度營業收入爲527,478美元,較2023年第三季度的554,654美元略有下降,同時實現了75%的毛利率,相比去年66%有所改善。公司的旗艦產品Enfinity銷量增加10%,達到2,616台,儘管Empower產品銷量下降了40%。營業費用從去年同期的115萬增加到131萬。公司通過在2024年9月完成700萬的公開發行來增強其財務狀況,發行了2857萬股股票和Warrants。此外,Elevai通過收購兩項關鍵許可擴展了其產品組合 - 一項價值100萬的幹細胞製劑科技許可和從Moa Life Plus獲得的專有工程益生菌產品許可。管理層實施了戰略變革,包括高管重組,任命Graydon Bensler爲首席執行官,Braeden Lichti爲董事長。公司還通過減少員工人數來簡化運營,並獲得了20萬美元的循環信貸額度。截至2024年9月30日,Elevai保持了643萬的現金儲備和610萬的營運資本。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息